| MeSH term | MeSH ID | Detail |
|---|---|---|
| Scorpion Stings | D065008 | 1 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| End Stage Liver Disease | D058625 | 1 associated lipids |
| Candidiasis, Invasive | D058365 | 2 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Central Serous Chorioretinopathy | D056833 | 1 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
| Pancreatitis, Graft | D055589 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Primary Graft Dysfunction | D055031 | 1 associated lipids |
| Idiopathic Interstitial Pneumonias | D054988 | 1 associated lipids |
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Dysuria | D053159 | 1 associated lipids |
| Nocturia | D053158 | 1 associated lipids |
| Delayed Graft Function | D051799 | 2 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Lymphohistiocytosis, Hemophagocytic | D051359 | 1 associated lipids |
| Granulomatosis, Orofacial | D051261 | 2 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Dyslipidemias | D050171 | 7 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Hepatic Insufficiency | D048550 | 1 associated lipids |
| Colitis, Collagenous | D046729 | 1 associated lipids |
| Protoporphyria, Erythropoietic | D046351 | 1 associated lipids |
| Coproporphyria, Hereditary | D046349 | 1 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Intestinal Volvulus | D045822 | 1 associated lipids |
| Cholecystolithiasis | D041761 | 2 associated lipids |
| Mastocytosis, Cutaneous | D034701 | 1 associated lipids |
| Hypoalbuminemia | D034141 | 1 associated lipids |
| Hyperuricemia | D033461 | 4 associated lipids |
| Papillomavirus Infections | D030361 | 4 associated lipids |
| Denys-Drash Syndrome | D030321 | 1 associated lipids |
| Pulmonary Disease, Chronic Obstructive | D029424 | 16 associated lipids |
| Polyomavirus Infections | D027601 | 1 associated lipids |
| Coronary Stenosis | D023921 | 6 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Brachial Plexus Neuritis | D020968 | 2 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Hypoxia-Ischemia, Brain | D020925 | 22 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Nervous System Autoimmune Disease, Experimental | D020721 | 3 associated lipids |
| Stroke | D020521 | 32 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Ventricular Remodeling | D020257 | 28 associated lipids |
| Infarction, Middle Cerebral Artery | D020244 | 35 associated lipids |
| Optic Nerve Injuries | D020221 | 4 associated lipids |
| Facial Nerve Injuries | D020220 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Nocturnal Myoclonus Syndrome | D020189 | 1 associated lipids |
| Sleep Apnea, Central | D020182 | 1 associated lipids |
| Citrullinemia | D020159 | 1 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Epstein-Barr Virus Infections | D020031 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Miller Fisher Syndrome | D019846 | 1 associated lipids |
| Hepatitis C, Chronic | D019698 | 12 associated lipids |
| Hepatitis B, Chronic | D019694 | 4 associated lipids |
| Hepatitis, Autoimmune | D019693 | 1 associated lipids |
| Neurodegenerative Diseases | D019636 | 32 associated lipids |
| Intracranial Hypertension | D019586 | 4 associated lipids |
| Dermatitis, Perioral | D019557 | 4 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Endotoxemia | D019446 | 27 associated lipids |
| Oral Ulcer | D019226 | 1 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Fasciitis, Necrotizing | D019115 | 1 associated lipids |
| Postoperative Hemorrhage | D019106 | 7 associated lipids |
| Multiple Endocrine Neoplasia Type 2a | D018813 | 1 associated lipids |
| Anemia, Iron-Deficiency | D018798 | 6 associated lipids |
| Encephalitis, Viral | D018792 | 3 associated lipids |
| Hypoplastic Left Heart Syndrome | D018636 | 1 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Lichen Sclerosus et Atrophicus | D018459 | 2 associated lipids |
| Vasculitis, Leukocytoclastic, Cutaneous | D018366 | 5 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Angiofibroma | D018322 | 2 associated lipids |
| Cervical Intraepithelial Neoplasia | D018290 | 1 associated lipids |
| Seminoma | D018239 | 2 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morris-Stiff G et al. | Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. | 1998 | Transplant. Proc. | pmid:9636525 |
| Claesson K et al. | Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. | 1998 | Transplant. Proc. | pmid:9636524 |
| Vanrenterghem Y et al. | Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. | 1998 | Transplant. Proc. | pmid:9636523 |
| Mendez R | FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636522 |
| Morris-Stiff G et al. | Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. | 1998 | Transplant. Proc. | pmid:9636521 |
| Rostaing L et al. | Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. | 1998 | Transplant. Proc. | pmid:9636520 |
| Rostaing L et al. | Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. | 1998 | Transplant. Proc. | pmid:9636519 |
| Uchida K et al. | Decreasing pancreatic toxicity of tacrolimus by dosage reduction. | 1998 | Transplant. Proc. | pmid:9636518 |
| Sato S et al. | Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. | 1998 | Transplant. Proc. | pmid:9636517 |
| Christiaans M et al. | Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. | 1998 | Transplant. Proc. | pmid:9636516 |
| van Duijnhoven E et al. | The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. | 1998 | Transplant. Proc. | pmid:9636515 |
| van Duijnhoven E et al. | Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. | 1998 | Transplant. Proc. | pmid:9636514 |
| Manzanares C et al. | Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. | 1998 | Transplant. Proc. | pmid:9636513 |
| Undre NA and Schäfer A | Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. | 1998 | Transplant. Proc. | pmid:9636512 |
| Jordan ML et al. | Tacrolimus for rescue of refractory renal allograft rejection. | 1998 | Transplant. Proc. | pmid:9636511 |
| Copley JB et al. | Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. | 1998 | Transplant. Proc. | pmid:9636510 |
| Kliem V et al. | Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. | 1998 | Transplant. Proc. | pmid:9636509 |
| Loss GE et al. | Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. | 1998 | Transplant. Proc. | pmid:9636508 |
| Busque S et al. | Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. | 1998 | Transplant. Proc. | pmid:9636507 |
| Morris-Stiff G et al. | Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. | 1998 | Transplant. Proc. | pmid:9636506 |
| Fernando ON et al. | Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. | 1998 | Transplant. Proc. | pmid:9636505 |
| Friemann S et al. | Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. | 1998 | Transplant. Proc. | pmid:9636504 |
| Budde K et al. | Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. | 1998 | Transplant. Proc. | pmid:9636503 |
| Carl S et al. | Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. | 1998 | Transplant. Proc. | pmid:9636502 |
| Turner CD et al. | Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. | 1998 | Transplant. Proc. | pmid:9636501 |
| Eghtesad B et al. | Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics. | 1998 | Transplant. Proc. | pmid:9636500 |
| Morris-Stiff G et al. | Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. | 1998 | Transplant. Proc. | pmid:9636499 |
| Kinukawa T et al. | Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. | 1998 | Transplant. Proc. | pmid:9636498 |
| Tanabe K et al. | Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. | 1998 | Transplant. Proc. | pmid:9636497 |
| Braun F et al. | Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. | 1998 | Transplant. Proc. | pmid:9636496 |
| Takahashi K et al. | Tacrolimus therapy for ABO-incompatible kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636495 |
| Jensik SC | Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636494 |
| Preston R et al. | FK 506 as primary immunosuppressive therapy in renal transplantation. | 1998 | Transplant. Proc. | pmid:9636493 |
| Miura S et al. | Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. | 1998 | Transplant. Proc. | pmid:9636492 |
| Fritsche L et al. | Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. | 1998 | Transplant. Proc. | pmid:9636481 |
| Marcus N et al. | Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. | 1998 | Transplant. Proc. | pmid:9636460 |
| Stempfle HU et al. | Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636459 |
| Walker RE et al. | Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation. | 1998 | Transplant. Proc. | pmid:9636452 |
| Undre NA et al. | Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. | 1998 | Transplant. Proc. | pmid:9636451 |
| Rieber J et al. | Effects of tacrolimus and cyclosporine on the coronary microcirculation after heart transplantation: a prospective study with serial intracoronary flow measurements. | 1998 | Transplant. Proc. | pmid:9636446 |
| Kobashigawa JA | Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. | 1998 | Transplant. Proc. | pmid:9636445 |
| Miki T et al. | Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. | 1998 | Transplant. Proc. | pmid:9636444 |
| Li S et al. | Intrathymic inoculation of donor bone marrow at the time of transplantation plus a short course of tacrolimus induce long-term acceptance to rat lung allografts. | 1998 | Transplant. Proc. | pmid:9636431 |
| Chen H et al. | FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. | 1998 | Transplant. Proc. | pmid:9636419 |
| Yura H et al. | Development of a macromolecular prodrug of FK 506: II: In vitro study for FK 506-dextran conjugate. | 1998 | Transplant. Proc. | pmid:9636416 |
| Yoshimura N et al. | Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate. | 1998 | Transplant. Proc. | pmid:9636415 |
| Fujimura T et al. | Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636413 |
| Isobe M et al. | Downregulation of endothelin expression in allograft coronary arteries after gene therapy targeting Cdk2 kinase. | 1998 | Transplant. Proc. | pmid:9636407 |
| McAlister VC | Liposomal tacrolimus: drug migration within blood compartments. | 1998 | Transplant. Proc. | pmid:9636404 |
| Krüger B et al. | Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. | 1998 | Transplant. Proc. | pmid:9636399 |